Research-use catalog page
COA request, lot visibility, availability, and schema stay aligned.
GHRP-6 is a hexapeptide GHS-R1a agonist and the founding GHRP compound — studied in preclinical models for GH release, significant appetite stimulation, and cortisol co-stimulation via ghrelin receptor activation.
Currently unavailable
This product is listed for research reference. It is not currently available for ordering. Live alternatives from the same research category are shown below.
This product is listed for research reference and is not currently available for ordering. See live alternatives below or contact the team.
Notify me when availableNeed the COA before you order? Request it here.
In your order
Lyophilized vial
Sterile-filtered, freeze-dried peptide in glass vial, sealed under inert gas.
Lot ID on every vial
Printed lot ID ties this exact vial to its analytical record.
COA on request
Independent third-party HPLC certificate, matched to your lot, sent on request.
Carrier-tracked shipping
Shipped from a US facility with full carrier tracking and protective packaging.
The Peptific standard
Peptide quality is invisible until it isn’t. Lot identity, purity, fill integrity, and chain of custody are the difference between usable research material and wasted budget.
Third-party HPLC tested
Every lot is tested for identity and purity by an independent analytical lab. Certificate of Analysis available on request, tied to the exact lot you receive.
Lyophilized and lot-tracked
Sterile-filtered, freeze-dried, sealed under inert gas. Each vial carries its own lot ID — full chain of custody from fill to delivery.
US-based fulfillment
Orders ship from a temperature-controlled US facility with carrier tracking. No drop-shipping, no opaque overseas relay.
Real support, not a ticket queue
A real person responds to research questions, lot questions, and order questions — usually same business day. No bot triage.
How it works
GHRP-6 activates GHS-R1a (ghrelin receptor) on pituitary somatotropes (GH release) and hypothalamic feeding circuits (appetite stimulation). Unlike ipamorelin, it produces significant cortisol and prolactin co-stimulation at GH-effective doses. Its ghrelin-mimetic appetite effect is the most pronounced of any characterized GHRP, making it valuable for appetite and feeding behavior research.
Compound profile
Product definition
GHRP-6 is a hexapeptide GHS-R1a agonist and the founding GHRP compound — studied in preclinical models for GH release, significant appetite stimulation, and cortisol co-stimulation via ghrelin receptor activation.
GHRP-6 (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) was synthesized by Cyril Bowers' group at Tulane University and represents the first synthetic hexapeptide GH secretagogue to be broadly characterized in the literature. It established the GHRP pharmacological class before the ghrelin receptor (GHS-R1a) was cloned, and its characterization helped identify the endogenous receptor that ghrelin (discovered later) naturally activates. The compound's appetitive effects emerge from GHS-R1a distribution in hypothalamic feeding circuits — the same receptor population that mediates ghrelin's orexigenic effects. At doses that produce robust GH release, GHRP-6 simultaneously activates hypothalamic GHS-R1a to stimulate food intake in rodent models. This dual GH/appetite axis engagement is pharmacologically distinct from the other major GHRPs and provides a research rationale for GHRP-6 in appetite biology studies that is not replicated by ipamorelin or GHRP-2.
Research audience
GHRP-6 is used by researchers studying GHS-R1a pharmacology, appetite and feeding behavior, ghrelin receptor biology, GH secretagogue history and mechanism, and hypothalamic feeding circuit pharmacology. It is the reference founding GHRP for any research requiring the full physiological GHS-R1a activation profile.
Research context
GHRP-6 was developed in Bowers' lab as part of a systematic program to identify non-peptide GH secretagogues for clinical development. The original GHRP program at Tulane characterized GHRP-6 and its structure-activity relationships, established the receptor class that would later be identified as GHS-R1a, and provided the pharmacological framework for subsequent GHRP development including GHRP-2, ipamorelin, and hexarelin. The appetite stimulation research emerged from observations that GHRP-6-treated animals exhibited increased food intake independently of GH levels. This observation paralleled the subsequent discovery of ghrelin (the endogenous GHS-R1a ligand, also a hunger signal) — establishing that the GHRP class activates the endogenous appetite-regulating receptor. GHRP-6 remains the standard research tool for studying this appetite dimension of GHS-R1a pharmacology because its effects are the most pronounced in this dimension compared to other GHRPs. In the historical context, GHRP-6 is the compound that demonstrated GH could be pharmacologically stimulated via a synthetic non-GHRH peptide — a finding that opened the entire GH secretagogue drug development field and ultimately led to the discovery of ghrelin, the ghrelin receptor, and the subsequent therapeutic applications in obesity and metabolic disease.
Common questions
Research Use Only
Sold for laboratory and research purposes only. Not approved for, nor intended for, human or veterinary consumption, diagnostic use, or therapeutic application. These products have not been evaluated by the Food and Drug Administration. Keep out of reach of children. For use by qualified researchers only.
Nothing on this page constitutes medical advice, a treatment recommendation, or a clinical protocol. Consult a qualified healthcare provider before making any health or treatment decisions.
By accessing this product page you confirm that you are a qualified researcher aged 18 or older and that you will use this product solely for lawful laboratory research purposes. View Research Use Policy
This product is listed for research reference and is not currently available for ordering. See live alternatives below or contact the team.
Notify me when availableAvailable now
These products from the same research category are currently available for ordering.
You might also want to check out these products.
2X Blend CJC-1295 Without DAC / Ipamorelin
The 2X Blend combines CJC-1295 Without DAC and Ipamorelin — the standard GHRH+GHRP research combination producing synergistic, selective GH pulse amplification through two independent receptor systems.
CJC-1295 Without DAC
CJC-1295 Without DAC (MOD GRF 1-29) is a tetrasubstituted GHRH(1-29) analog with ~30-minute half-life — the preferred short-acting GHRH analog for pulsatile GH research protocols, commonly paired with ipamorelin.
CJC-1295 With DAC
CJC-1295 With DAC is a long-acting GHRH analog with albumin-binding modification that sustains elevated GH and IGF-1 for 6–8 days per administration in preclinical and early clinical research.
Ipamorelin
Ipamorelin is a selective pentapeptide GHRP studied in preclinical models for GH release without cortisol or prolactin elevation — the most selective GHRP in its class.
IGF-1LR3
IGF-1 LR3 is an 83-amino-acid IGF-1 analog with reduced IGFBP binding, extending half-life from ~15 minutes to ~20–30 hours — the most studied long-acting IGF-1 analog in preclinical research.
Hexarelin Acetate
Hexarelin (Examorelin) is the most potent characterized GHRP hexapeptide — GHS-R1a agonist with Phase II human data and unique CD36 cardiac receptor binding providing GH-independent cardioprotection in animal models.
IGF-DES
Tesamorelin
Tesamorelin is a 44-amino-acid GHRH analog with N-terminal trans-3-hexenoic acid modification — the only FDA-approved GHRH peptide, validated in Phase III trials for visceral adiposity reduction.
Sermorelin
Sermorelin is a 29-amino-acid synthetic GHRH(1-29) analog — the first FDA-approved GHRH peptide (Geref), with the longest published research history of any synthetic GHRH compound.
MOD GRF 1-29
MOD GRF 1-29 (CJC-1295 Without DAC) is a tetrasubstituted GHRH(1-29) analog with ~30-minute half-life — the most commonly used short-acting GHRH compound for pulsatile GH secretion research.
GHRP-2
GHRP-2 (Pralmorelin) is a synthetic hexapeptide GHS-R1a agonist approved in Japan for GH stimulation testing — a potent non-selective GHRP that stimulates GH alongside cortisol and prolactin.
$25.00
$12.00
$30.00
$29.00